JP MORGAN/CALL/ABBOTT LABORATORIES/165/0.1/16.01.26 Stock

Warrant

DE000JK50Z98

Market Closed - Börse Stuttgart 09:47:21 2024-05-27 am EDT
0.088 EUR -7.37% Intraday chart for JP MORGAN/CALL/ABBOTT LABORATORIES/165/0.1/16.01.26
Current month-32.14%
1 month-32.14%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-27 0.088 -7.37%
24-05-24 0.095 -4.04%
24-05-23 0.099 +20.73%
24-05-22 0.082 -4.65%
24-05-21 0.086 -3.37%

Delayed Quote Börse Stuttgart

Last update May 27, 2024 at 09:47 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ABBOTT LABORATORIES
Issuer J.P. Morgan
WKN JK50Z9
ISINDE000JK50Z98
Date issued 2024-04-04
Strike 165 $
Maturity 2026-01-16 (599 Days)
Parity 10 : 1
Emission price 0.18
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.21
Lowest since issue 0.082
Spread 0.304
Spread %77.95%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
104 USD
Average target price
125.7 USD
Spread / Average Target
+20.92%
Consensus